Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- Conditions
- Cancer of Unknown Primary Site
- Interventions
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 528
- Registration Number
- NCT03498521
- Locations
- 🇫🇷
Centre Antoine Lacassagne, Nice, France
🇫🇷Institut Curie, Paris, France
🇫🇷CHU Lyon - Centre Hospitalier Lyon Sud, Pierre-Benite (Lyon), France
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
- Conditions
- Early Breast Cancer
- Interventions
- Drug: FDC of Pertuzumab and Trastuzumab SCProcedure: SurgeryRadiation: Post-operative Radiotherapy
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 500
- Registration Number
- NCT03493854
- Locations
- 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
🇯🇵St. Luke's International Hospital, Tokyo, Japan
🇧🇪Institut Jules Bordet, Anderlecht, Belgium
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 149
- Registration Number
- NCT03491150
- Locations
- 🇺🇸
Anderson Clinical Research, Inc., Redlands, California, United States
🇺🇸University of California, Davis; Alzheimers Disease Center, Department of Neurology, Sacramento, California, United States
🇫🇷Hopital La Grave; Place Lange, Toulouse Cedec, France
An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps
- Conditions
- Nasal PolypsChronic Rhinosinusitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 249
- Registration Number
- NCT03478930
- Locations
- 🇺🇸
Jonathan Corren MD, Inc., Los Angeles, California, United States
🇺🇸Brigham and Womens Hospital, Boston, Massachusetts, United States
🇺🇸Vitae Research Center, Miami, Florida, United States
A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT03478956
- Locations
- 🇵🇱
Centrum Zdrowia MDM, Warszawa, Poland
🇪🇸Hospital Niño Jesus; Servicio de Pediatria - Gastrenterologia y Nutricion, Madrid, Spain
🇬🇧Royal Manchester Childrens Hospital, Manchester, United Kingdom
Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Device: Accu-Chek® Solo micropump systemDevice: mylife™ OmniPod® Insulin Management SystemOther: Multiple Daily Injections (MDI) therapy
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 181
- Registration Number
- NCT03478969
- Locations
- 🇦🇹
Hietzing Hospital, Vienna, Austria
🇩🇪Diabetes Klinik Bad Mergentheim GmbH, Bad Mergentheim, Germany
🇩🇪InnoDiab Forschung GmbH, Essen, Germany
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
- Conditions
- B-Cell LymphomaNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 111
- Registration Number
- NCT03467373
- Locations
- 🇩🇰
Rigshospitalet, København Ø, Denmark
🇫🇷Hopital Claude Huriez, Lille, France
🇫🇷Hopital Hotel Dieu Et Hme, Nantes, France
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
- Conditions
- Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 453
- Registration Number
- NCT03456063
- Locations
- 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇪🇸Hospital Regional Universitario Carlos Haya, Malaga, Spain
🇪🇸Hospital Universitario Virgen Macarena, Sevilla, Spain
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 257
- Registration Number
- NCT03456076
- Locations
- 🇷🇺
Pavlov First Saint Petersburg State Medical University, St. Petersburg, Sankt Petersburg, Russian Federation
🇷🇺Scientific Research Oncology Institute named after N.N. Petrov; Oncology, St. Petersburg, Sankt Petersburg, Russian Federation
🇷🇺GUZ Regional clinical hospital # 1, Krasnodar, Russian Federation
Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2018-03-05
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1
- Registration Number
- NCT03454243
- Locations
- 🇺🇸
START, San Antonio, Texas, United States